The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -7,102,455 | -16,188,206 |
| Stock compensation expense | 1,445,480 | 2,831,783 |
| Depreciation and amortization | 21,292 | 27,429 |
| Loss on share settlement of kineta employee compensation assumed from merger | 185,019 | - |
| Change in fair value of kineta merger holdback shares | 315,660 | - |
| Other current assets | -222,659 | -110,418 |
| Other noncurrent assets | -39,804 | 70,380 |
| Accounts payable and accrued expenses | -6,214,003 | 2,302,372 |
| Net cash flows from operating activities | -11,086,544 | -10,986,584 |
| Cash paid for business acquisition, net of cash received from kineta | 0 | 1,259,278 |
| Purchase of property and equipment | 0 | 48,233 |
| Net cash flows from investing activities | 0 | -1,307,511 |
| Cash dividend payment of preferred stock series a | 2,089 | 4,178 |
| Proceeds from warrants exercised | 0 | 3,620,657 |
| Proceeds from issuance of common stock | 6,197,547 | 5,914,625 |
| Payment of debt assumed from kineta merger | 434,000 | - |
| Payment of deferred offering costs | - | 331,363 |
| Payment of note payables to former kineta employees | 98,677 | - |
| Payment of transaction costs related to kintara merger | 0 | 500,000 |
| Principal payments of finance lease | 43,671 | - |
| Payment of placement agent fees and offering costs | 679,337 | - |
| Payment of net liabilities assumed in reverse recapitalization with kintara | 0 | 550,000 |
| Net cash flows from financing activities | 5,271,136 | 8,149,741 |
| Net change in cash and cash equivalents | -5,815,408 | -4,144,354 |
| Cash and cash equivalents at beginning of period | 12,657,178 | - |
| Cash and cash equivalents at end of period | 2,697,416 | - |
TuHURA Biosciences, Inc. NV (HURA)
TuHURA Biosciences, Inc. NV (HURA)